Bajaj Healthcare Ltd

Bajaj Healthcare maintains a conservative capital structure with a debt-to-equity ratio of 0.48, below the median for the Pharmaceuticals industry, and a current ratio of 1.89, indicating strong short-term liquidity. Free cash flow of INR 565.5 million supports operational flexibility, though capital expenditures of INR -115.4 million suggest a focus on cost optimization rather than expansion. Profitability metrics show a return on equity of 8.47% and a return on assets of 4.74%, both below the industry median for Pharmaceuticals, indicating room for improvement in asset utilization and shareholder returns. Gross profit of INR 2.56 billion and operating income of INR 576.1 million reflect a healthy margin profile, but net income of INR 394.96 million suggests pressure from operating expenses or interest costs. The company operates through three segments: APIs, Finished Dosage Formulations (FDFs), and Intermediates. APIs and FDFs are the primary revenue drivers, with the latter offering a diverse range of tablet, capsule, and powder formulations. Geographic exposure is concentrated in India, with no material international revenue disclosed in the latest financials. Outlook for the current fiscal year shows a projected revenue growth of 12.3% year-over-year, driven by increased demand for APIs and FDFs. The next fiscal year is expected to see a 9.8% growth, though this is slightly below the industry average, reflecting potential market saturation or competitive pressures. Risk assessment highlights a medium liquidity risk due to negative net cash after subtracting total debt, and a low dilution risk based on stable share counts and no recent equity issuance. However, the company's reliance on domestic markets and exposure to regulatory changes in the pharmaceutical sector remain key concerns. Recent filings and transcripts indicate a focus on cost optimization and product diversification. The company has not disclosed any major capital-raising activities or strategic acquisitions in the past 12 months, suggesting a conservative approach to growth.